Syndax Pharmaceuticals Inc Cash Flow Statement
SNDX / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
Syndax Pharmaceuticals Inc used $323M in operating cash flow and negative free cash flow of $323M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | -$56.0M | -$74.0M | -$60.8M | -$44.5M | -$24.1M | -$19.8M | -$24.1M | -$19.8M |
| Depreciation & Amortization | - | - | - | - | $90.0K | - | $76.0K | $89.0K | $21.0K | $15.0K | $21.0K | $15.0K |
| Operating Cash Flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | -$50.6M | -$68.5M | -$47.4M | -$35.2M | -$2.4M | -$14.4M | -$2.4M | -$14.4M |
| Capital Expenditures | $187.0K | $0 | $0 | $0 | $129.0K | $187.0K | $84.0K | $261.0K | $49.0K | $4.0K | $49.0K | $4.0K |
| Free Cash Flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | -$50.7M | -$68.7M | -$47.5M | -$35.4M | -$2.5M | -$14.4M | -$2.5M | -$14.4M |
| FCF Margin | -187.5% | -1160.9% | - | - | -3344.8% | -4529.9% | -2251.2% | -2903.1% | -395.1% | -2296.2% | - | - |